Drogueria MK LAB S.a.c Pharmaceutical Import Profile — Peru (DGFT 2022–2026)

Name: Drogueria MK LAB S.a.c Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Drogueria MK LAB S.a.c — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Drogueria MK LAB S.a.c

Pharmaceutical Importer · Peru · Other Focus · $1.1M Total Trade · DGFT Verified

Drogueria MK LAB S.a.c is a pharmaceutical importer based in Peru with a total trade value of $1.1M across 2 products in 2 therapeutic categories. Based on 23 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Drogueria MK LAB S.a.c sources from 3 verified Indian suppliers, with Reliance Life Sciences Private Limited accounting for 96.6% of imports.

Drogueria MK LAB S.a.c — Import Portfolio & Supplier Network

Drogueria MK LAB S.a.c import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Drogueria MK LAB S.a.c?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Reliance Life Sciences Private Limited	$2.4M	76	96.6%
Til Healthcare Private Limited	$50.0K	1	2.0%
Serum Institute Of India Private Limited

What Formulations Does Drogueria MK LAB S.a.c Import?

Formulation	Value	Ships
Human normal immunoglobulin for	$500.0K	10
Relipoietin 2000 IU INJ (recombinant human erythropoietin injection (rhuepo) 2000 IU) (qty: 62000 pfs)	$368.3K	8
Relipoietin 2000 IU INJ recombinant	$300.0K	11
Relipoietin 2000 IU INJ recombinant human erythropoietin injection (rhuepo) 2000iu	$257.0K	10
Human normal immunoglobulin for intravenous administration b.p.5% solution 100ML(immunorel 5% 100ML)	$150.0K	3
Immunorel 5% 100ML human normal immunoglobulin for intravenous administration b.p., 5% solution 100ML	$127.3K	4
Human normal immunoglobulin for intravenous administration b p 5 solution 100ML immunorel 5 100ML	$100.0K	2
Relipoietin 2000 IU INJ recombinant human erythropoietin injection (rhuepo)	$57.4K	3
Relipoietin 2000 IU INJ recombinant human erythropoietin injection rhuepo 2000iu	$50.0K	1
Human normal immunoglobulin for intravenous administration b p 5 solution 100ML immunorel 5 100 ML	$50.0K	1
Samples - astymin liquid - 200ML	$50.0K	1
Human normal immnunoglobulin for intravenous administration b.p.5% solution 100ML ( immmunorel 5% 100ML)	$50.0K	1
Rituximab 500MG (rituxirel 500MG)	$50.0K	1
Human albumin solution b p 20 solution 50ML alburel 20 50ML	$50.0K	1
Human albumin solution b.p. 20%	$44.9K	1

Drogueria MK LAB S.a.c imports 35 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Immunoglobulin	Other	$1.1M	21	0.4%	5
2	Rituximab	Advanced Oncology	$100.0K	2	0.5%	9

Drogueria MK LAB S.a.c imports 2 pharmaceutical products across 2 categories into Peru totaling $1.1M.

Drogueria MK LAB S.a.c — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Drogueria MK LAB S.A.C., commonly known as MK LAB, is a Peruvian company specializing in the importation and commercialization of pharmaceutical products, particularly biologicals, blood derivatives, and biosimilars. Established in 2016, the company is headquartered in Surquillo, Lima, Peru. Its mission is to be the leading choice in the pharmaceutical sector, aiming to become strategic partners with clients, suppliers, and collaborators by offering quality products at the forefront of pharmaceutical science and technology. (mklab.pe)

MK LAB's product portfolio is divided into two main business lines: biological products and nutritional supplements. The company emphasizes efficiency, respect, trust, and responsibility in its operations, fostering an ethically professional environment. As of March 2025, MK LAB employed 16 individuals and engaged 7 service providers.

2Distribution Network

MK LAB operates multiple facilities to support its distribution network. The administrative office is located at Jr. Víctor Mantilla N° 237, Int. 1-3, Urb. Barrio Médico, Surquillo, Lima. The primary warehouse (Warehouse 1) is situated at Jr. Víctor Mantilla N° 245, 1st Floor, Urb. Barrio Surquillo, Surquillo, Lima, with storage services provided by Droguería ESKE CORPORATION S.A.C. An additional warehouse (Warehouse 2) is located at Av. Santa Ana, Urb. Primavera, Mz. A-31, Lote 40, Santa Anita, Lima. (digemid.minsa.gob.pe)

While specific details about MK LAB's logistics capabilities and geographic coverage beyond Lima are limited, the company's strategic partnerships with international laboratories in India, South Korea, and China suggest a robust supply chain capable of meeting national demand. (mklab.pe)

3Industry Role

MK LAB functions primarily as a pharmaceutical importer and wholesaler in Peru's supply chain. By sourcing specialized pharmaceutical products from international suppliers, the company plays a crucial role in ensuring the availability of essential medications within the Peruvian market. Its focus on biologicals and biosimilars indicates a commitment to providing advanced therapeutic options to meet the evolving healthcare needs of the population. (mklab.pe)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Drogueria MK LAB S.a.c

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

MK LAB's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.1 million USD from India across 23 shipments. The top five imported products, including immunoglobulin and rituximab, account for 100% of the company's imports, indicating a portfolio entirely dependent on these items. This concentration suggests a strategic focus on specific high-demand therapeutic areas but also presents potential risks associated with supply chain disruptions or regulatory changes affecting these products.

The company's reliance on a limited number of suppliers—three verified Indian suppliers—raises questions about the stability and resilience of its supply chain. While the consistent sourcing from these suppliers may indicate strong relationships, the lack of diversification could expose MK LAB to vulnerabilities if any of these suppliers face operational challenges or regulatory issues.

2Supply Chain Resilience

MK LAB's supply chain resilience appears limited due to its concentrated sourcing from a few suppliers. The absence of backup suppliers and the focus on a narrow range of formulations suggest potential challenges in maintaining a steady supply of products. Additionally, the company's reliance on specific shipping routes and ports, such as the Port of Callao, could expose it to logistical disruptions. Ensuring compliance with international regulatory standards, including those set by the World Health Organization (WHO), is essential for maintaining product quality and uninterrupted supply.

Importing Pharmaceuticals into Peru — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Peru

1Regulatory Authority & Framework

In Peru, the Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) is the primary regulatory authority overseeing the importation and commercialization of pharmaceutical products. DIGEMID is responsible for ensuring that imported medications comply with national health standards and regulations. Key legislation governing pharmaceutical imports includes the General Health Law and the Pharmaceutical Products Regulation, which outline the requirements for marketing authorization, quality control, and distribution of pharmaceutical products.

The marketing authorization pathway for Indian generics involves submitting a comprehensive dossier to DIGEMID, demonstrating compliance with Peruvian standards. This process includes providing evidence of Good Manufacturing Practice (GMP) certification, product stability data, and clinical efficacy studies. Approval from DIGEMID is mandatory before any pharmaceutical product can be marketed in Peru.

2Import Licensing & GMP

Import licensing in Peru requires importers to obtain authorization from DIGEMID, ensuring that all imported pharmaceutical products meet national health and safety standards. GMP certification is a critical component of this process; Peruvian authorities recognize certifications from reputable organizations such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from these recognized bodies to facilitate the importation process.

Drogueria MK LAB S.a.c — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

MK LAB's focus on biologicals and biosimilars aligns with the growing demand for advanced therapeutic options in Peru. Biological products, including monoclonal antibodies like rituximab, offer targeted treatments for various conditions, while biosimilars provide cost-effective alternatives to expensive biologics. The importation of immunoglobulin addresses critical needs in immunodeficiency disorders. This strategic focus enables MK LAB to cater to specialized medical needs, positioning itself as a key player in the Peruvian pharmaceutical market.

2Sourcing Profile

MK LAB's sourcing strategy emphasizes importing finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, from India. This approach allows the company to offer ready-to-use products that meet international quality standards. India's robust pharmaceutical manufacturing sector, with its adherence to recognized GMP certifications, makes it a reliable source for these products. By focusing on finished formulations, MK LAB can streamline its supply chain and ensure timely delivery of products to the Peruvian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Drogueria MK LAB S.a.c

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with MK LAB, given the company's focus on importing biologicals and biosimilars. Suppliers that can provide high-quality, GMP-certified products in these categories may find a receptive partner in MK LAB. However, the existing concentration of MK LAB's sourcing suggests that any new supplier would need to offer compelling value propositions, such as competitive pricing, reliable supply chains, and adherence to Peruvian regulatory standards, to gain a foothold in the company's portfolio.

2Requirements & Qualifications

Indian exporters seeking to supply MK LAB and the Peruvian market must ensure that their products are manufactured in facilities holding valid GMP certifications recognized by Peruvian authorities, such

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Drogueria MK LAB S.a.c

What products does Drogueria MK LAB S.a.c import from India?

Drogueria MK LAB S.a.c imports 2 pharmaceutical products across 2 categories. Top imports: Immunoglobulin ($1.1M), Rituximab ($100.0K).

Who supplies pharmaceuticals to Drogueria MK LAB S.a.c from India?

Drogueria MK LAB S.a.c sources from 3 verified Indian suppliers. The primary supplier is Reliance Life Sciences Private Limited (96.6% of imports, $2.4M).

What is Drogueria MK LAB S.a.c's total pharmaceutical import value?

Drogueria MK LAB S.a.c's total pharmaceutical import value from India is $1.1M, based on 23 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Drogueria MK LAB S.a.c focus on?

Drogueria MK LAB S.a.c imports across 2 categories. The largest: Other (91.3%), Advanced Oncology (8.7%).

Get Full Drogueria MK LAB S.a.c Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.